OTCPK:HALB - Post by User
Post by
AveragePennyon Apr 25, 2022 11:05am
43 Views
Post# 34628925
Halberd CEO Letter
Halberd CEO Letter Q1 OVERVIEW AND ACHIEVEMENTS
- Halberd demonstrated elimination of the final two of the "Top Ten" antigens linked to neurodegenerative diseases.
- Halberd demonstrated that its antigen elimination process is able to selectively eliminate target antigens from cerebral spinal fluid (CSF).
- Halberd investigations revealed that it's proprietary Covid-19 antibody demonstrated a high affinity to the Covid Omicron variant - the only antibody among six competitive antibodies tested which binds to Covid-19, the Delta variant and the Omicron variant.
- Halberd added a microbiology expert, Dr. Chester Cooper, to its advisory staff to guide and advance the company's investigations into the extracorporeal elimination of E. coli bacteria, which is responsible for hundreds of thousands of deaths in the US from meningitis and blood sepsis.
- Halberd added Dr. Ravi Durvasula, a renowned infectious disease specialist, to its advisory staff to help guide Halberd through the next development stages of the application of its technology - animal testing and human clinical trials.
- Halberd successfully completed the audit of its financials and is awaiting sign-off of the completed Form 10 by the auditor. Form 10 will be filed immediately after sign-off.
2Q GOALS
- Complete the addition of a DVM/PhD candidate to plan and execute extensive animal testing of Halberd's patented extracorporeal process for the removal of targeted disease antigens.
- Complete the research of the removal of select target antigens from blood serum.
- Complete and publish a scientific article on our revolutionary R&D achievements.
- Contact select Big Pharma candidates for the purposes of exploring potential joint venture opportunities.
- Develop program with NFL Retired Players' Association President seeking to secure NFL support/endorsement of our R&D into finding cures/treatments for traumatic brain injury TBI/ chronic traumatic encephalopathy (CTE) leading to potential neurodegenerative diseases in life after football.
- Work with NCAA contacts seeking their support/endorsement of our R&D into finding cures/treatments for traumatic brain injury TBI/ chronic traumatic encephalopathy (CTE).
- Develop plans for initiation of animal testing of our R&D for cures/treatments for TBI/CTE.
- Initiate testing of Halberd's patent pending chemical bonding process for extracorporeal elimination of select disease antigens from bodily fluids, which would eliminate the need for laser or radio frequency irradiation.
- Evaluate potential organizational changes which would allow Halberd to better focus on simultaneous R&D programs with different technologies.
- Continue efforts to evaluate potential NFT program involving Halberd's technology.
- Improve communication of Halberd's technology to the public via various media channels.
- Evaluate Contract Research Organizations (CRO) to assist in scoping out the costs and timing of activities directed at obtaining FDA certification.
- Contact FDA to establish potential for Emergency Use Authorization of Halberd's technology for select conditions and afflictions.